Tandem Diabetes Care Inc (TNDM) Stock Price & Analysis
Tandem Diabetes Care Inc (TNDM) fell 4.66% to USD 17.61 as of June 10, 2026 at 00:37 UTC, according to Nexqual real-time market data.
TNDM last closed at USD 18.47; the session ranged USD 17.5–18.83 on volume of 2,553,520 shares. Market capitalization is $1.21B, with a 52-week range of USD 9.98–29.65 (NGM). Source: Nexqual, June 10, 2026 at 00:37 UTC.
Key Statistics (as of June 10, 2026 at 00:37 UTC)
| Price | USD 17.61 |
|---|---|
| Change | ▼ 4.66% (down) |
| Previous Close | USD 18.47 |
| Open | USD 18.64 |
| Day Range | USD 17.5 – 18.83 |
| 52-Week Range | USD 9.98 – 29.65 |
| Volume | 2,553,520 shares |
| Market Cap | $1.21B |
| Exchange | NGM |
Technical Analysis (TNDM)
Nexqual's technical model rates TNDM "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:37 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.14 (neutral) |
| vs SMA50 | Below (USD 18.04) |
| MACD | 0.24 (positive) |
Analyst Ratings (TNDM)
Wall Street analysts rate TNDM "Buy" based on 20 analysts, with a mean price target of USD 29.2 (range USD 17–50), per Nexqual as of June 10, 2026 at 00:37 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 29.2 |
| High Target | USD 50 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 13 / 10 / 0 |
Earnings (TNDM)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $254.95M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.3 vs est -0.44 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.09 ▲ beat |
| 2025-09-30 | USD -0.31 vs est -0.34 ▲ beat |
| 2025-06-30 | USD -0.48 vs est -0.4 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:37 UTC.
Financials & Fundamentals (TNDM)
| Total Revenue | $1.03B |
|---|---|
| Revenue Growth (YoY) | +5.50% |
| Gross Margin | +54.93% |
| Operating Margin | -7.05% |
| Profit Margin | -9.20% |
| ROE | -65.73% |
| Debt / Equity | 554.92 |
| Current Ratio | 3.58 |
| Total Cash | $570.26M |
| Total Debt | $734.73M |
| Free Cash Flow | $-20.26M |
Source: Nexqual, June 10, 2026 at 00:37 UTC.
Financial Health Score (TNDM)
Nexqual rates Tandem Diabetes Care Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:37 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 55%, operating -7% |
| Balance Sheet | Weak — $570M cash vs $735M debt |
| Cash Flow | Weak — FCF negative: -$20M, burning cash |
| Efficiency | Critical — ROE -66%, ROA -3.7% |
Ownership (TNDM)
| Insider Ownership | +0.97% |
|---|---|
| Institutional Ownership | +117.89% |
| Shares Outstanding | 68.53M |
| Float | 62.92M |
| Short % of Float | +23.16% |
Source: Nexqual, June 10, 2026 at 00:37 UTC.
Leadership (TNDM)
Tandem Diabetes Care Inc is led by John F. Sheridan (age 70), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:37 UTC.
| President, CEO & Director | John F. Sheridan (age 70) |
|---|---|
| Executive VP, CFO & Treasurer | Leigh A. Vosseller (age 52) |
| Executive VP and Chief Strategy & Product Officer | Elizabeth Anne Gasser (age 49) |
| Executive VP & COO | Jean-Claude E. Kyrillos (age 61) |
| Executive VP & CTO | Rick A. Carpenter (age 62) |
Major Backers & Investors (TNDM)
Notable institutional backers of Tandem Diabetes Care Inc include Sessa Capital IM, L.P., ArrowMark Colorado Holdings LLC, GW&K Investment Management, LLC, according to Nexqual as of June 10, 2026 at 00:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sessa Capital IM, L.P. | 6.9% |
| ArrowMark Colorado Holdings LLC | 4.53% |
| GW&K Investment Management, LLC | 3.92% |
| Driehaus Capital Management, LLC | 3.36% |
| Goldman Sachs | 3.24% |
| Citadel | 3.2% |
| Fidelity | 0.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.96% |
| Vanguard Group | 20.18% |
| State Street | 4.79% |
Source: Nexqual, June 10, 2026 at 00:37 UTC.
From Tandem Diabetes Care Inc's Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
- It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
- The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body.
- In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PODD | Insulet Corporation | USD 159.61 | ▲ 4.17% |
| DXCM | DexCom, Inc. | USD 78.19 | ▲ 7.32% |
| NVCR | NovoCure Limited | USD 17.24 | ▲ 0.47% |
| CDNA | CareDx, Inc. | USD 22.75 | ▲ 2.25% |
| GH | Guardant Health, Inc. | USD 130.12 | ▲ 3.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:37 UTC. This page is informational and not investment advice.